SinoMab BioScience Ltd

SinoMab BioScience Limited is a biopharmaceutical company that researches, develops, manufactures, and commercializes therapeutics for immunological diseases, primarily monoclonal antibody (mAb)-based biologics, in Mainland China and Hong Kong. Its pipeline includes SM03 (Suciraslimab), a first-in-class anti-CD22 mAb in Phase III for rheumatoid arthritis and in Phase II for non-Hodgkin's lymphoma and systemic lupus erythematosus, and in Phase I for Alzheimer's disease and Sjögren's syndrome. The company also develops SM17, a humanized anti-IL-25 receptor in Phase I for asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SN1011, a Bruton's tyrosine kinase inhibitor in Phase II for pemphigus, neuromyelitis optica spectrum disorder, multiple sclerosis, and systemic lupus erythematosus; and preclinical candidates SM06 and SM09 (humanised anti-CD22), an anti-CGC antibody for vitiligo and alopecia areata, and a bispecific antibody candidate for osteoporosis. Incorporated in 2001, SinoMab BioScience Limited is headquartered in Tai Po, Hong Kong.